马来酸曲美布汀联合胃肠安丸治疗腹泻型肠易激综合征的临床疗效

Clinical curative effect of Trimebutine Maleate combined with Weichang'an pill in the treatment of irritable bowel syndrome

目的对马来酸曲美布汀联合胃肠安丸治疗腹泻型肠易激综合征(IBS-D)的临床疗效进行初步探讨。方法将128例IBS-D患者随机分为两组,65例进入马来酸曲美布汀组(单药组),63例进入马来酸曲美布汀联合胃肠安丸组(联合用药组),两组患者服药4周。结果单药组患者经治疗后,症状自评量表(SCL-90)躯体化得分、健康相关生活质量(QOL)得分上和治疗前相比差异有统计学意义(P<0.05);匹兹堡睡眠质量量表(PSQI)得分和治疗前对比差异无统计学意义。临床治疗有效率为71.9%(46/64)。联合用药组患者与治疗前对比,SCL-90躯体化得分、QOL得分、PSQI得分比较差异有统计学意义(P<0.05)。临床治疗有效率为82.5%(52/63)。联合用药组疗效优于单药组。结论马来酸曲美布汀联合胃肠安丸在IBS-D的治疗上值得临床广泛推广和应用。

Objective To investigate the Clinical curative effect of Trimebutine Maleate combined with Weichang'an pill in the treatment of irritablebowel syndrome.Methods A randomized controlled trial(which including128IBS-D patients)was carried Sixty-five patients entered theTrimebutine Maleate group(Single drug group)and63patients were in theTrimebutine Maleate combined with Weichang'an pill group(Combineddrug group).Two groups of patients were required to completed the course of treatment,which was4weeks.Results After the single drug treatment,there were statistical differences in the scores of symptom checklist90(SCL-90)somatization part and health-related quality of life(QOL)compared with before treatment(P<0.05),however,in the total score of pittsburgh sleep quality index(PSQI),there was no difference.Clinical effectiverate was71.9%(46/64).With the combined drug group,there were statistical differences in the scores of SCL-90somatization part and QOL togetherwith PSQI compared with before treatment(P<0.05).Clinical effective rate was82.5%(52/63).The efficacy of the combined drug group wasbetter than that of the single drug group.Conclusion Trimebutine Maleate combined with Weichang'an pill was worthy of extensive promotion andapplication in the treatment of IBS-D.